Hope therapeutics, inc. and nrx pharmaceuticals, inc. (nasdaq:nrxp) announce kadima neuropsychiatry institute as the expected first acquisition for its international network of interventional psychiatry clinics

Kadima neuropsychiatry institute in la jolla, ca to serve as flagship for an international network of clinics dedicated to treating depression and ptsd kadima's founder, david feifel, md, phd, professor emeritus of psychiatry at university of california san diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and ptsd, to join hope as chief medical innovation officer kadima is a leading investigative site for cns and psychedelic research, and has served as the lead site in nearly all major clinical trials in this area acquisition expected to be immediately accretive to revenue and ebitda for nrx miami , jan. 2, 2025 /prnewswire/ -- hope therapeutics, inc., ("hope," the "company"), a medical and technology driven company, and a wholly-owned subsidiary of nrx pharmaceuticals, inc. ("nrx") (nasdaq: nrxp), today announced the planned acquisition of the kadima neuropsychiatry institute (kadima) of la jolla, ca, per the previously announced letter of intent, for the hope network. kadima is expected to serve as the flagship clinic for hope's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and ptsd.
NRXP Ratings Summary
NRXP Quant Ranking